Eli Lilly's brenipatide program takes this further
Metabolism is very flexible
Judson RN, Quarta M, Oudhoff MJ, Soliman H, Yi L, Chang CK, Loi G, Vander Werff R, Cait A, Hamer M, Blonigan J, Paine P, Doan LTN, Groppa E, He W, Su L, Zhang RH, Xu P, Eisner C, Low M, Barta I, Lewis CB, Zaph C, Karimi MM, Rando TA, Rossi FM
Both Novo Nordisk and Eli Lilly have invested heavily in expanding manufacturing infrastructure for oral GLP-1 therapies, including facilities across North Carolina, Texas, Alabama, and Puerto Rico
Underlying diabetes and vascular disease remain the most significant contributors
In December 2025, the FDA approved the first oral GLP-1 pill for weight management, and compounding pharmacies have introduced oral disintegrating tablet (ODT) formulations that bypass the digestive system entirely